



Referrals are invited for patients with radiotherapy-induced bleeding for the PPALM Study

This randomised double blind placebo controlled, NIHR approved trial of oral medication with Gamma Tocotrienol (an extract of Palm oil) and Pentoxifylline is recruiting patients with new onset rectal bleeding affecting quality of life and due to radiation-induced telangiectasia who are free of other abnormal GI symptoms.

There is a 2:1 randomisation to the active treatment arm v placebo.

Key Inclusion Criteria

- Past history of a malignant pelvic neoplasm (T1-4 N0-2 M0) of the rectum, prostate, testis, bladder, uterine cervix, uterus, vagina, vulva, anal canal or ovary including radiotherapy .
- >12 months follow-up post-radiotherapy (24 months for patients with past history of stage T4 and/or N2 disease).
- <7 years post-radiotherapy
- No evidence of cancer recurrence.

Key Exclusion Criteria:

- Previous surgery for rectal cancer.
- Ischaemic heart disease, uncontrolled hypertension, hypotension, acute myocardial infarction, cerebral haemorrhage, retinal haemorrhage, renal failure, liver failure and medication with insulin, ketorolac or vitamin K.

For further details or to arrange referral contact:

Jennifer Matthews, trial coordinator

Jennifer.matthews@rmh.nhs.uk

Tel: 0207 352 8171 ext. 1515

The trial Principal Investigator is

Dr. Jervoise Andreyev,

Consultant Gastroenterologist,

Jervoise.Andreyev@rmh.nhs.uk

Tel: 0207 811 8216